OXiGENE'S Chief Scientific Officer, Dr. David Chaplin, to Present at the ''BIO 2006'' Annual International Convention

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leadingdeveloper of biopharmaceutical compounds to treat cancer and certainophthalmologic diseases, announced today that David Chaplin, Ph.D.,Head of Research and Development and the Company's Chief ScientificOfficer, plans to present at the "BIO 2006" Annual InternationalConvention at the McCormick Place Convention Center in Chicago, IL.The Annual Convention of the Biotechnology Industry Organization (BIO)is the world's largest biotechnology conference, focusing on newcancer therapies and cutting-edge innovations in science. Dr. Chaplinis scheduled to present on Monday, April 10, 2006 at 2:30 p.m., CT inRoom B, McCormick Place South, Level 3, Exhibit Hall A. BIO is not webcasting presentations at this Convention.

About OXiGENE, Inc.

OXiGENE is an emerging pharmaceutical company developing novelsmall-molecule therapeutics to treat cancer and eye diseases. TheCompany's major focus is the clinical advancement of drug candidatesthat selectively disrupt abnormal blood vessels associated with solidtumor progression and visual impairment. OXiGENE is dedicated toleveraging its intellectual property position and therapeuticdevelopment expertise to bring life saving and enhancing medicines topatients.

Safe Harbor Statement

Certain statements in this news release may be considered"forward-looking statements" within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Any or all of theforward-looking statements in this press release may turn out to bewrong. They can be affected by inaccurate assumptions OXiGENE mightmake or by known or unknown risks and uncertainties, including, butnot limited to: the early stage of product development; the ability tosecure necessary patents; uncertainties as to the future success ofongoing and planned clinical trials; and the unproven safety andefficacy of products under development. Consequently, noforward-looking statement can be guaranteed, and actual results mayvary materially. Additional information concerning factors that couldcause actual results to materially differ from those in theforward-looking statements is contained in OXiGENE's reports to theSecurities and Exchange Commission, including OXiGENE's reports onForm 10-Q, Form 8-K and Form 10-K. However, OXiGENE undertakes noobligation to publicly update forward-looking statements, whetherbecause of new information, future events or otherwise.